Prostatype Genomics says 20-year follow-up study shows Prostatype low-risk group records zero prostate cancer deaths

Bitget2026/09/30 14:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prostatype Genomics presented new long-term Prostatype study results at the Swedish Urological Association’s annual meeting in Växjö today.
Study from Uppsala University Hospital followed 137 prostate cancer patients for about 20 years on average from diagnosis.
Patients labeled low-risk by Prostatype recorded no prostate cancer deaths during follow-up, supporting confidence in ruling out aggressive disease.
Results indicated Prostatype outperformed the NCCN risk framework in identifying patients likely to die from prostate cancer.
Data has been submitted for peer review, bolstering evidence cited in the product’s Medicare reimbursement review in the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prostatype Genomics says 20-year follow-up study shows Prostatype low-risk group records zero prostate cancer deaths

You may also like

Crypto prices